Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 Shares

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CFO Daniel Calkins sold 4,110 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $5.13, for a total transaction of $21,084.30. Following the completion of the transaction, the chief financial officer now directly owns 109,945 shares in the company, valued at $564,017.85. This trade represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Daniel Calkins also recently made the following trade(s):

• On Monday, June 23rd, Daniel Calkins sold 25 shares of Verastem stock. The shares were sold at an average price of $4.71, for a total transaction of $117.75.
• On Tuesday, May 20th, Daniel Calkins sold 11,143 shares of Verastem stock. The stock was sold at an average price of $8.13, for a total value of $90,592.59.

Verastem Stock Performance

Shares of NASDAQ:VSTM traded down $0.06 during trading on Tuesday, hitting $4.56. 2,536,656 shares of the company were exchanged, compared to its average volume of 1,476,434. Verastem, Inc. has a 52-week low of $2.10 and a 52-week high of $9.10. The stock has a 50 day moving average of $6.70 and a 200 day moving average of $6.01. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.50 and a quick ratio of 3.50. The company has a market cap of $250.57 million, a PE ratio of -1.43 and a beta of 0.85.

Verastem (NASDAQ:VSTM - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.24). As a group, equities research analysts predict that Verastem, Inc. will post -3.02 EPS for the current year.

Institutional Trading of Verastem

A number of hedge funds and other institutional investors have recently bought and sold shares of VSTM. Tower Research Capital LLC TRC boosted its holdings in Verastem by 51.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 1,698 shares during the period. ProShare Advisors LLC bought a new stake in Verastem during the fourth quarter valued at $56,000. Voya Investment Management LLC purchased a new position in Verastem during the fourth quarter worth about $59,000. Sherbrooke Park Advisers LLC purchased a new position in Verastem during the fourth quarter worth about $61,000. Finally, The Manufacturers Life Insurance Company bought a new position in Verastem in the 4th quarter worth about $74,000. Institutional investors own 88.37% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Mizuho lowered their target price on Verastem from $9.00 to $8.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Royal Bank Of Canada decreased their price objective on shares of Verastem from $16.00 to $14.00 and set an "outperform" rating for the company in a report on Friday, March 21st. Wall Street Zen cut shares of Verastem from a "hold" rating to a "sell" rating in a research note on Friday, April 18th. HC Wainwright increased their target price on shares of Verastem from $10.00 to $14.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Finally, Jefferies Financial Group began coverage on shares of Verastem in a research note on Thursday, April 10th. They set a "buy" rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $13.63.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.